Search results
Jump to navigation
Jump to search
Page title matches
- {{dambigbox|the New York Heart Association Functional Classification|New York}} The '''New York Heart Association Functional Classification''' is:<ref name="NYHA-classification">{{cite book |author=The Criteria Comm2 KB (272 words) - 13:05, 7 February 2023
- 12 bytes (1 word) - 10:04, 23 January 2008
- 191 bytes (29 words) - 04:45, 8 September 2009
- Auto-populated based on [[Special:WhatLinksHere/New York Heart Association Functional Classification]]. Needs checking by a human.565 bytes (72 words) - 18:59, 11 January 2010
Page text matches
- #REDIRECT [[New York Heart Association Functional Classification]]66 bytes (7 words) - 15:50, 25 February 2011
- {{rpl|New York Heart Association Functional Classification}}391 bytes (60 words) - 13:01, 7 February 2023
- {{dambigbox|the New York Heart Association Functional Classification|New York}} The '''New York Heart Association Functional Classification''' is:<ref name="NYHA-classification">{{cite book |author=The Criteria Comm2 KB (272 words) - 13:05, 7 February 2023
- Auto-populated based on [[Special:WhatLinksHere/New York Heart Association Functional Classification]]. Needs checking by a human.565 bytes (72 words) - 18:59, 11 January 2010
- {{r|New York Heart Association Functional Classification}}805 bytes (103 words) - 18:04, 11 January 2010
- ...ng patients with an [[ventricular ejection fraction]] of 40% of less and [[New York Heart Association Functional Classification]] class I-III [[heart failure]] according to the ATHENA [[randomized contro ...east one episode of shortness of breath on minimal exertion or at rest ([[New York Heart Association Functional Classification|New York Heart Association]] [NYHA] functional class III or IV) or paroxys2 KB (288 words) - 22:25, 7 July 2011
- ...}} </ref><br/>2010||2737 patients<br/>• EF≤35%<br/>• [[New York Heart Association Functional Classification|NYHA Class II]]|| [[eplerenone]] up to 50 mg/day||Placebo|| mortality at 21 ...}} </ref><br/>1999||1663 patients<br/>• EF≤35%<br/>• [[New York Heart Association Functional Classification|NYHA Class III/IV]]|| [[spironolactone]] 25 mg/day||Placebo|| mortality at6 KB (789 words) - 00:07, 21 February 2011
- ...compared with symptom-guided treatment." Symptoms were measured with the [[New York Heart Association Functional Classification]].<ref name="pmid19176440">{{cite journal| author=Pfisterer M, Buser P, Ric ...ombination treatment reduces mortality in African-American patients with [[New York Heart Association Functional Classification|functional class]] III or IV heart failure.<ref name="pmid15533851">{{cite73 KB (10,150 words) - 21:46, 20 August 2014
- * [[New York Heart Association Functional Classification]]25 KB (3,396 words) - 13:29, 2 April 2024
- ** Decompensated [[heart failure]] ([[New York Heart Association Functional Classification|NYHA functional class]] IV; worsening or new-onset HF)81 KB (10,863 words) - 17:35, 10 February 2024